ANNEXON INC. - COMMON STOCK

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

08 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

03 Apr 2025 18:18:29 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

17 Mar 2025 16:05:37 By Nasdaq GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

03 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

26 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

13 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

13 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Dec 2024 16:05:00 By Nasdaq GlobeNewswire

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

16 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

05 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

15 Nov 2024 16:59:57 By Nasdaq GlobeNewswire

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

14 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

13 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

21 Oct 2024 20:00:41 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Sep 2024 08:00:00 By Nasdaq GlobeNewswire